The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.
Jeff Kiefer,Robert L. Vessella,Robert L. Vessella,Janna E. Quinn,Austin M. Odman,Jian Zhang,Evan T. Keller,Paul J. Kostenuik,Colin R. Dunstan,Eva Corey +9 more
TL;DR: A potential role for OPG is suggested in the treatment of established osteoblastic CaP bone metastases in an animal model using LuCaP 23.1 cells as a model for evaluating serum prostate specific antigen (PSA).
read more
Abstract: Osteoprotegerin (OPG) plays a central role in controlling bone resorption. Exogenous administration of OPG has been shown to be effective in preventing osteolysis and limiting the growth of osteolytic metastasis. The objective of this study was to investigate the effects of OPG on osteoblastic prostate cancer (CaP) metastases in an animal model. LuCaP 23.1 cells were injected intra-tibially and Fc-OPG (6.0 mg/kg) was administered subcutaneously three times a week starting either 24 hours prior to cell injection (prevention regimen) or at 4 weeks post-injection (treatment regimen). Changes in bone mineral density at the tumor site were determined by dual x-ray absorptiometry. Tumor growth was monitored by evaluating serum prostate specific antigen (PSA). Fc-OPG did not inhibit establishment of osteoblastic bone lesions of LuCaP 23.1, but it decreased growth of the tumor cells, as determined by decreases in serum PSA levels of 73.0 +/- 44.3% (P < 0.001) and 78.3 +/- 25.3% (P < 0.001) under the treatment and prevention regimens, respectively, compared to the untreated tumor-bearing animals. Administration of Fc-OPG decreased the proliferative index by 35.0% (P = 0.1838) in the treatment group, and 75.2% (P = 0.0358) in the prevention group. The results of this study suggest a potential role for OPG in the treatment of established osteoblastic CaP bone metastases.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Bone metastasis: the importance of the neighbourhood
Peter I. Croucher,Peter I. Croucher,Michelle M. McDonald,Michelle M. McDonald,T. John Martin,T. John Martin +5 more
TL;DR: The role of different bone cell types in supporting disseminated tumour cell dormancy and reactivation is discussed, and the new opportunities this provides for targeting the bone microenvironment to control dormancies and bone metastasis are highlighted.
432
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Allison P. Armstrong,Robert E. Miller,Jon Jones,Jian Zhang,Evan T. Keller,William C. Dougall +5 more
TL;DR: This work has shown that receptor activator of NF‐κB ligand (RANKL) inhibition decreases bone lesion development and tumor growth in bone, suggesting that RANKL may play a direct role on tumor cells.
Prostate Cancer and Bone Metastases: The Underlying Mechanisms.
Sok Kuan Wong,Nur-Vaizura Mohamad,Tijjani Rabiu Giaze,Kok-Yong Chin,Norazlina Mohamed,Soelaiman Ima-Nirwana +5 more
TL;DR: The possible molecular mechanisms involved in governing bone metastases driven by prostate cancer are outlined, which further provide the basis in searching for new molecular targets for the development of potential therapy.
154
Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells
TL;DR: PCa preclinical model cell lines and their sublines, PDXs, and patient-derived organoid and spheroid PCa models in 3-dimensional culture are reviewed for retaining the characteristics of patient tumors.
149
RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
TL;DR: This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RankL.
131
References
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
William S. Simonet,David L. Lacey,Colin R. Dunstan,Michael J. Kelley,Ming-Shi Chang,R Lüthy,Hung Q. Nguyen,S Wooden,L Bennett,Tom Boone,Grant Shimamoto,Margaret L. DeRose,Robin Elliott,Anne Colombero,Hong-Lin Tan,Geraldine Trail,John K. Sullivan,E. Davy,N. Bucay,L Renshaw-Gegg,T.M Hughes,Dave Hill,W Pattison,Patricia Shehan Campbell,S Sander,Gwyneth Van,John E. Tarpley,P Derby,Richard Lee,William J. Boyle +29 more
TL;DR: Data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.
5.3K
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
N. Bucay,Ildiko Sarosi,Colin R. Dunstan,Sean Morony,John E. Tarpley,C. Capparelli,S. Scully,Hong Lin Tan,Weilong Xu,David L. Lacey,William J. Boyle,William S. Simonet +11 more
TL;DR: It is demonstrated that OPG is a critical regulator of postnatal bone mass and regulation of OPG, its signaling pathway, or its ligand(s) may play a role in the long observed association between osteoporosis and vascular calcification.
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
TL;DR: Modulation of these systems provides a unique opportunity to design novel therapeutics to inhibit bone loss in arthritis, periodontal disease, and osteoporosis.
846
Breast cancer cells interact with osteoblasts to support osteoclast formation.
Rachel J. Thomas,Theresa A. Guise,J J Yin,J Elliott,Nicole J. Horwood,Thomas J. Martin,Matthew T. Gillespie +6 more
TL;DR: Using a murine model of breast cancer metastasis to bone, it is established that MCF-7 cells that overexpress PTHrP caused significantly more bone metastases, which were associated with increased osteoclast formation, elevated plasma P THrP concentrations and hypercalcaemia compared with parental or empty vector controls.
524
The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.
TL;DR: A computer simulation of the bone‐remodeling transient is described, in which the focus is explicitly on changes in clinically measurable bone mass (or density) and the importance of separating the response across the first remodeling period from bone changes that may ensue thereafter.
296
Related Papers (5)
William S. Simonet,David L. Lacey,Colin R. Dunstan,Michael J. Kelley,Ming-Shi Chang,R Lüthy,Hung Q. Nguyen,S Wooden,L Bennett,Tom Boone,Grant Shimamoto,Margaret L. DeRose,Robin Elliott,Anne Colombero,Hong-Lin Tan,Geraldine Trail,John K. Sullivan,E. Davy,N. Bucay,L Renshaw-Gegg,T.M Hughes,Dave Hill,W Pattison,Patricia Shehan Campbell,S Sander,Gwyneth Van,John E. Tarpley,P Derby,Richard Lee,William J. Boyle +29 more